Skip Navigation

Advertise|Press|Contact|FAQ|CWConnect

Bookmark/Print/Share

Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: Immunology | Oncology | Hematology

Cutaneous T-Cell Lymphoma Clinical Trials


A listing of Cutaneous T-Cell Lymphoma medical research trials actively recruiting patient volunteers. Click on the closest city to find more detailed information on a research study in your area.

Alabama

Birmingham : University of Alabama - Birmingham

Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL

California

Stanford : Stanford Cancer Center

A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma

Stanford : Stanford University School of Medicine

Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma

Stanford : Stanford Medical Center

Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL

Illinois

Chicago : Northwestern Memorial Hospital

A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma

Massachusetts

Boston : Boston University Medical Center

A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma

Boston : Boston Medical Center

Everolimus in Treating Cutaneous T-cell Lymphoma

Missouri

St. Louis : Washington University School of Medicine

Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL

New Jersey

Hackensack : John Theurer Cancer Center (Hackensack University Medical Center)

A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma

New York

New York : Memorial Sloan-Kettering Cancer Center

Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma

Rochester : University of Rochester School of Medicine

Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL

Pennsylvania

Philadelphia : Fox Chase Cancer Center

Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma

Pittsburgh : University of Pittsburgh

A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma

Pittsburgh : University of Pittsburgh School of Medicine

Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma

Texas

Houston : MD Anderson Cancer Center

A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma

Houston : MD Anderson Cancer Center

Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma

Australia

Concord : Concord Repatriation General Hospital

A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma

East Melbourne : Peter MacCallum Cancer Centre

A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma

Nedlands : Sir Charles Gairdner Hospital

A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma

Belgium

Leuven : UZ Leuven

A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma

Germany

Kiel : Klinik für Dermatologie, Venerologie und Allergologie

A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma

Italy

Bologna : A.O.U. Policlinico S.Orsola Malpighi

A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma

Bologna : Ospedale Sant'Orsola - Policlinico Sant'Orsola

Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma

Spain

Madrid : Hospital Universitario 12 de Octubre

A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma

United Kingdom

Leeds : St. James University Hospital

A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma

London : St. John's Institute of Dermatology

A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma

Manchester : Manchester Cancer Research Centre

A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma